Long-term follow-up of dual CD19/CD22 CAR-T-cell therapy, as #Monotherapy and with autologous #StemCellTransplantation, in TP53-altered relapsed/refractory B-cell non-#HodgkinLymphoma patients, reveals clinical benefit & manageable toxicity.
#OpenAccess: doi.org/10.1038/s413...